Abstract
Ribonucleotide reductase is an essential enzyme for DNA synthesis in all prokaryotic and eukaryotic cells; it catalyses the reductive conversion of ribonucleotides to deoxyribonucleotides. Several herpesviruses including herpes simplex virus type 1 (HSV-1)1, HSV-22, pseudorabies virus (PRV)3, equine herpesvirus type 1 (EHV-1)4 and Epstein–Barr virus (EBV)5 have been found to induce novel ribonucleotide reductase activities. There is evidence that the HSV-1 ribonucleotide reductase activity is virus-encoded6 and essential for virus replication7. This makes herpesvirus ribonucleotide reductases potential targets for antiviral chemotherapy. The HSV-1-encoded enzyme consists of two summits8,9,18: V136, the large subunit of relative molecular mass (Mr) 136,000 (136K) (RR1), which has been shown to be essential for enzyme activity7, and V38, the small subunit (RR2) which forms a complex with the large subunit and is also likely to be essential for enzyme activity9. Two particular features of the enzyme make it an attractive antiviral target. First, there is evidence for a common, highly conserved herpesvirus ribonucleotide reductase and second, the interaction between the large and small subunits may itself be exploitable. Here we identify a synthetic peptide which specifically inhibits the activity of virus-induced enzyme. We deduce that the mechanism of inhibition involves interference with the normal interaction between the two types of subunit.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cohen, G. H. J. Virol. 9, 408–418 (1972).
Cohen, G. H., Factor, M. N. & Ponce De Leon, M. J. Virol. 14, 20–25 (1974).
Lankinen, H., Graslund, A. & Thelander, L. J. Virol. 41, 893–900 (1982).
Cohen, J. C., Henry, B. E., Randall, C. C. & O'Callaghan, D. J. Proc. Soc. exp. Biol. Med. 155, 395–399 (1977).
Henry, B. E., Glaser, R., Hewetson, J. & O'Callaghan, D. J. Virology 89, 262–271 (1978).
Dutia, B. M. J. gen. Virol. 64, 513–521 (1983).
Preston, V. G., Palfreyman, J. W. & Dutia, B. M. J. gen. Virol. 66, 1581–1587 (1984).
Cohen, E. A., Charron, J., Perret, J. & Langelier, Y. J. gen. Virol. 66, 733–745 (1985).
Frame, M. C., Marsden, H. S. & Dutia, B. M. J. gen. Virol. 66, 1581–1587 (1985).
McGeoch, D. J., Dolan, A., Donald, S. & Rixon, F. 0. molec. Biol. 181, 1–13 (1985).
Standart, N. M., Bray, S. J., George, E. L., Hunt, T. & Ruderman, J. V. J. Cell Biol. 100, 1968–1976 (1985).
McLauchlan, J. & Clements, J. B. J. gen. Virol. 64, 997–1006 (1983).
McLauchlan, J. & Clements, J. B. EMBO J. 2, 1953–1961 (1983).
Carlson, J., Fuchs, J. A. & Messing, J. Proc. natn. Acad. Sci. U.S.A. 81, 4294–4297 (1984).
Gibson, T., Stockwell, P., Ginsberg, M. & Barrell, B. Nucleic Acids Res. 12, 5087–5099 (1984).
Davison, A. J. & Scott, J. E. J. gen. Virol. (in the press).
Sjoberg, B.-M. et al. FEBS Lett. 183, 99–102 (1985).
Bachetti, S., Evelegh, M. J. & Muirhead, B. J. Virol 57, 1177–1181 (1986).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dutia, B., Frame, M., Subak-Sharpe, J. et al. Specific inhibition of herpesvirus ribonucleotide reductase by synthetic peptides. Nature 321, 439–441 (1986). https://doi.org/10.1038/321439a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/321439a0
This article is cited by
-
TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress
Communications Biology (2022)
-
Genome and network visualization facilitates the analyses of the effects of drugs and mutations on protein-protein and drug-protein networks
BMC Bioinformatics (2016)
-
In silico design of peptidic inhibitors targeting estrogen receptor alpha dimer interface
Molecular Diversity (2012)
-
Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets
Nature Reviews Drug Discovery (2003)
-
A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo
Nature (1994)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.